The bill requires the Executive Office of Health and Human Services to submit a quarterly report detailing the projected total costs for the upcoming fiscal year related to pharmaceutical pipeline drugs. This report will include information on drugs identified by the executive office that are expected to be available for utilization within a 12-month period. The current report indicates that 71 pipeline market entries from 76 manufacturers are anticipated to be available between January 1, 2026, and December 31, 2026, with an estimated expenditure of approximately $20 million for all MassHealth members.

Additionally, the report highlights that high-cost cell and gene therapies are significant contributors to the projected spending. The previous quarterly report had estimated a similar expenditure based on 50 pipeline market entries from 61 manufacturers. The bill emphasizes the importance of transparency in pharmaceutical costs and the need for ongoing monitoring of drug availability and associated expenses. For further inquiries regarding the report, contact information for Sarah Nordberg-Dunlea is provided.